BACKGROUND: Recurrence and/or metastasis occurs in more than half of patients with head and neck squamous cell carcinoma (HNSCC), and these events pose the greatest threats to long-term survival. We set out to identify genetic alterations that underlie recurrent/metastatic HNSCC. METHODS: Whole-exome sequencing (WES) was performed on genomic DNA extracted from fresh-frozen whole blood and patient-matched tumor pairs from 13 HNSCC patients with synchronous lymph node metastases and 10 patients with metachronous recurrent tumors. Mutational concordance within and between tumor pairs was used to analyze the spatiotemporal evolution of HNSCC in individual patients and to identify potential therapeutic targets for functional evaluation. RESULTS: Approximately 86% and 60% of single somatic nucleotide variants (SSNVs) identified in synchronous nodal metastases and metachronous recurrent tumors, respectively, were transmitted from the primary index tumor. Genes that were mutated in more than one metastatic or recurrent tumor, but not in the respective primary tumors, include C17orf104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor tyrosine kinase 2 (DDR2). Select DDR2 mutations have been shown to confer enhanced sensitivity to SRC-family kinase (SFK) inhibitors in other malignancies. Similarly, HNSCC cell lines harboring endogenous and engineered DDR2 mutations were more sensitive to the SFK inhibitor dasatinib than those with WT DDR2. CONCLUSION: In this WES study of patient-matched tumor pairs in HNSCC, we found synchronous lymph node metastases to be genetically more similar to their paired index primary tumors than metachronous recurrent tumors. This study outlines a compendium of somatic mutations in primary, metastatic, and/or recurrent HNSCC cancers, with potential implications for precision medicine approaches. FUNDING: National Cancer Institute, American Cancer Society, Agency for Science, Technology and Research of Singapore, and Gilead Sciences Inc.
BACKGROUND: Recurrence and/or metastasis occurs in more than half of patients with head and neck squamous cell carcinoma (HNSCC), and these events pose the greatest threats to long-term survival. We set out to identify genetic alterations that underlie recurrent/metastatic HNSCC. METHODS: Whole-exome sequencing (WES) was performed on genomic DNA extracted from fresh-frozen whole blood and patient-matched tumor pairs from 13 HNSCC patients with synchronous lymph node metastases and 10 patients with metachronous recurrent tumors. Mutational concordance within and between tumor pairs was used to analyze the spatiotemporal evolution of HNSCC in individual patients and to identify potential therapeutic targets for functional evaluation. RESULTS: Approximately 86% and 60% of single somatic nucleotide variants (SSNVs) identified in synchronous nodal metastases and metachronous recurrent tumors, respectively, were transmitted from the primary index tumor. Genes that were mutated in more than one metastatic or recurrent tumor, but not in the respective primary tumors, include C17orf104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor tyrosine kinase 2 (DDR2). Select DDR2 mutations have been shown to confer enhanced sensitivity to SRC-family kinase (SFK) inhibitors in other malignancies. Similarly, HNSCC cell lines harboring endogenous and engineered DDR2 mutations were more sensitive to the SFK inhibitor dasatinib than those with WT DDR2. CONCLUSION: In this WES study of patient-matched tumor pairs in HNSCC, we found synchronous lymph node metastases to be genetically more similar to their paired index primary tumors than metachronous recurrent tumors. This study outlines a compendium of somatic mutations in primary, metastatic, and/or recurrent HNSCC cancers, with potential implications for precision medicine approaches. FUNDING: National Cancer Institute, American Cancer Society, Agency for Science, Technology and Research of Singapore, and Gilead Sciences Inc.
Authors: Laura E MacConaill; Elizabeth Garcia; Priyanka Shivdasani; Matthew Ducar; Ravali Adusumilli; Marc Breneiser; Mark Byrne; Lawrence Chung; Jodie Conneely; Lauren Crosby; Levi A Garraway; Xin Gong; William C Hahn; Charlie Hatton; Philip W Kantoff; Michael Kluk; Frank Kuo; Yonghui Jia; Ruchi Joshi; Janina Longtine; Allison Manning; Emanuele Palescandolo; Nematullah Sharaf; Lynette Sholl; Paul van Hummelen; Jacqueline Wade; Bruce M Wollinson; Dimity Zepf; Barrett J Rollins; Neal I Lindeman Journal: J Mol Diagn Date: 2014-08-23 Impact factor: 5.568
Authors: Andrew Roth; Jaswinder Khattra; Damian Yap; Adrian Wan; Emma Laks; Justina Biele; Gavin Ha; Samuel Aparicio; Alexandre Bouchard-Côté; Sohrab P Shah Journal: Nat Methods Date: 2014-03-16 Impact factor: 28.547
Authors: Zhang Yan; Su Jin; Zhang Wei; Hou Huilian; Yin Zhanhai; Teng Yue; Li Juan; Li Jing; Yao Libo; Li Xu Journal: Biochim Biophys Acta Date: 2014-04-27
Authors: Min Yu; Aditya Bardia; Nicola Aceto; Francesca Bersani; Marissa W Madden; Maria C Donaldson; Rushil Desai; Huili Zhu; Valentine Comaills; Zongli Zheng; Ben S Wittner; Petar Stojanov; Elena Brachtel; Dennis Sgroi; Ravi Kapur; Toshihiro Shioda; David T Ting; Sridhar Ramaswamy; Gad Getz; A John Iafrate; Cyril Benes; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Science Date: 2014-07-11 Impact factor: 47.728
Authors: Gerald Goh; Ute I Scholl; James M Healy; Murim Choi; Manju L Prasad; Carol Nelson-Williams; John W Kunstman; John W Kuntsman; Reju Korah; Anna-Carinna Suttorp; Dimo Dietrich; Matthias Haase; Holger S Willenberg; Peter Stålberg; Per Hellman; Göran Akerström; Peyman Björklund; Tobias Carling; Richard P Lifton Journal: Nat Genet Date: 2014-04-20 Impact factor: 38.330
Authors: Lei Huang; Odile David; Robert J Cabay; Klara Valyi-Nagy; Virgilia Macias; Rong Zhong; Barry Wenig; Lawrence Feldman; Ralph Weichselbaum; Michael T Spiotto Journal: Clin Cancer Res Date: 2018-12-20 Impact factor: 12.531
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Kent W Mouw; James M Cleary; Brendan Reardon; Jonathan Pike; Lior Z Braunstein; Jaegil Kim; Ali Amin-Mansour; Diana Miao; Alexis Damish; Joanna Chin; Patrick A Ott; Charles S Fuchs; Neil E Martin; Gad Getz; Scott Carter; Harvey J Mamon; Jason L Hornick; Eliezer M Van Allen; Alan D D'Andrea Journal: Clin Cancer Res Date: 2016-11-16 Impact factor: 12.531
Authors: Chang Xu; Olga Nikolova; Ryan S Basom; Ryan M Mitchell; Reid Shaw; Russell D Moser; Heuijoon Park; Kay E Gurley; Michael C Kao; Carlos L Green; Franz X Schaub; Robert L Diaz; Hallie A Swan; In S Jang; Justin Guinney; Vijayakrishna K Gadi; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: Joshua D Smith; Andrew C Birkeland; Andrew J Rosko; Rebecca C Hoesli; Susan K Foltin; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Gregory T Wolf; Carol R Bradford; Mark E Prince; John Chad Brenner; Matthew E Spector Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147